Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Psychiatry | Journal

Back to Journal Articles

Drug Beneficial in a Model of Post-Traumatic Stress Disorder

Last Updated: August 31, 2012.

 

Small molecule stabilizes a brain calcium channel

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Stress-induced cognitive disorders such as post-traumatic stress disorder are associated with dysfunction in a brain calcium channel, and stabilizing the channel with a small molecule can reverse the impairment in learning and memory in mice, according to a study published in the Aug. 31 issue of Cell.

FRIDAY, Aug. 31 (HealthDay News) -- Stress-induced cognitive disorders such as post-traumatic stress disorder are associated with dysfunction in a brain calcium channel, and stabilizing the channel with a small molecule can reverse the impairment in learning and memory in mice, according to a study published in the Aug. 31 issue of Cell.

Building on previous results showing that ryanodine receptors regulate intracellular calcium levels and that stress can cause leakiness in the channel in the heart resulting in heart failure and arrhythmias, Xiaoping Liu, Ph.D., from Columbia University in New York City, and colleagues examined whether the type 2 ryanodine receptor (RyR2), which is expressed in the brain's hippocampus, had a role in stress-induced cognitive dysfunction in a mouse model.

The researchers found that the chronically-stressed mice had leaky hippocampal RyR2 channels. The mice also had impaired cognitive function, as determined by tests of hippocampal-dependent learning and memory. Both the channel leakiness and impaired cognitive function could be reversed by a small-molecule compound that stabilized RyR2 channels.

"Thus, neuronal RyR2 remodeling contributes to stress-induced cognitive dysfunction," Liu and colleagues conclude. "Leaky RyR2 could be a therapeutic target for treatment of stress-induced cognitive dysfunction."

One author is a consultant for ARMGO Pharma, which is targeting RyR channels for therapeutic purposes.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: MRI Scanners Temporarily Impair Neurocognitive Function Next: Kidney Stones Increase Risk of Adverse Kidney Outcomes

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.